The Life Sciences team advised Absci Corporation on the closing of its initial public offering of 14,375,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,875,000 shares of common stock, at a public offering price of $16.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Absci were $230.0 million. Absci’s common stock began trading on the Nasdaq Global Select Market on July 22, 2021, under the ticker symbol “ABSI.” All shares in the offering were offered by Absci.

Absci is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. Absci built its Integrated Drug Creation™ Platform to accelerate discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single efficient process.

The Goodwin team was led by Maggie Wong and Kingsley Taft and included Alicia Tschirhart, Emily Wetmore, Flip Schmidt, Kevin KablerMegan Gustafson, Shane Albright, Alexander Varond, Roger Cohen, Heath Ingram, Sarah Bock, Daniel Karelitz, Brian Mukherjee and Brad Weber with invaluable assistance from James Matarese, Shira Borzak, Scott Zilora, Natasha Dimond and Tricia Hojo.

For additional details on the offering, please read the press release.